USSTOCK.TODAY
Market Closed
Log in Sign up

Viridian Therapeutics beats revenue estimates with Lumvoa launch

Earnings Whispers +1 · ·by G4L

VRDN
VRDN Viridian Therapeutics Inc
$30.19 +5.97%
View chart & analysis →
  1. 1Net product sales for the Lumvoa launch quarter reached $24.7 million.
  2. 2Viridian Therapeutics saw a 347.9% increase in total revenue, exceeding the $5.75 million consensus for the launch quarter.
  3. 3Viridian Therapeutics management stated that the product launch exceeded expectations.

So what's the key point?

Viridian Therapeutics' new drug sold much more than expected. The company reported strong results with $24.7 million in sales, which was much higher than what experts had predicted.

Source Earnings Whispers +1 · View original ↗

Related 3-line summaries

Viridian Therapeutics Set to Announce Q3 Results: Divergence Between Stock Rise and Earnings Decline Earnings Whispers · Oct 28L.B. Foster reports Q3 revenue growth and raises annual guidance The Motley Fool +1 · 4d agoTwin Disc reports $3.4 million in first quarter profit Associated Press +1 · 4d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news